Log in to save to my catalogue

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5125250

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

About this item

Full title

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Publisher

Waltham, MA: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2012-11, Vol.367 (19), p.1783-1791

Language

English

Formats

Publication information

Publisher

Waltham, MA: Massachusetts Medical Society

More information

Scope and Contents

Contents

Women with metastatic breast cancer that had progressed during treatment with trastuzumab plus a taxane were assigned to lapatinib plus capecitabine or to trastuzumab emtansine. The response rate and survival were significantly better with trastuzumab emtansine.
Amplification of human epidermal growth factor receptor 2 (HER2, also called ErbB2)...

Alternative Titles

Full title

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5125250

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5125250

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1209124

How to access this item